Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

The "Enterprise Tech Ecosystem Series: Bayer AG 2024" report has been added to ResearchAndMarkets.com's offering. The report provides insights into Bayer AG's tech activities, including its digital ...

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the ...

Advancements and Projections in the Global Radiopharmaceuticals Market: Insights, Trends, Opportunities, and Recent ...

Dr. Marijn Dekkers, Bayer chief executive, 2010-2016 However, before we get into the history of this German pharmaceutical company, it’s a good idea to get your head around the different names ...

A Washington jury ordered Bayer to pay $100 million to individuals sickened by toxic PCBs at a Seattle school, marking the latest courtroom challenge for the company. Meanwhile, Pfizer is reducing its ...

Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...